[Novel Current and Future Therapy Options for Treatment of Dry Eye Disease]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2017 Nov 15

PMID 29134276

Citations 3

Authors

E M Messmer

Affiliations

Soon will be listed here.

Abstract

Dry eye disease was redefined by the dry eye workshop (DEWS II) in May 2017. According to the new definition "dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms". The current definition encompasses etiological factors, such as instability and hyperosmolarity of the tear film, ocular surface inflammation and damage as well as a new aspect compared to the former definition, neurosensory abnormalities. Recent and future therapeutic options for dry eye focus on treatment of the aforementioned pathogenetic events. New tear substitutes, medications and devices to stimulate tear production, innovative anti-inflammatory treatment, medications to influence corneal innervation and new methods for treatment of Meibomian gland dysfunction are already available or will be available in the near future.

Citing Articles

Overview of CFTR activators and their recent studies for dry eye disease: a review.

Wu J, Wang X, Zhao Y, Hou Y, Gong P RSC Med Chem. 2023; 14(12):2459-2472.

PMID: 38107177 PMC: 10718525. DOI: 10.1039/d3md00448a.

Effects of Serial Sessions of Activa Mask for the Treatment of Meibomian Gland Dysfunction.

Vigo L, Pellegrini M, DAngelo S, Carones F, Scorcia V, Giannaccare G Ophthalmol Ther. 2022; 12(1):209-216.

PMID: 36327001 PMC: 9834468. DOI: 10.1007/s40123-022-00604-w.

Bacteria and Dry Eye: A Narrative Review.

Wang Y, Ding Y, Jiang X, Yang J, Li X J Clin Med. 2022; 11(14).

PMID: 35887783 PMC: 9319739. DOI: 10.3390/jcm11144019.

References

Schmidt T, Sullivan D, Knop E, Richards S, Knop N, Liu S . Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol. 2013; 131(6):766-76. PMC: 3887468. DOI: 10.1001/jamaophthalmol.2013.2385. View

Bonini S, Rama P, Olzi D, Lambiase A . Neurotrophic keratitis. Eye (Lond). 2003; 17(8):989-95. DOI: 10.1038/sj.eye.6700616. View

Brown M, Brown G, Brown H, Peet J, Roth Z . Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009; 127(2):146-52. DOI: 10.1001/archophthalmol.2008.608. View

Craig J, Chen Y, Turnbull P . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2015; 56(3):1965-70. DOI: 10.1167/iovs.14-15764. View

Lemp M, Crews L, Bron A, Foulks G, Sullivan B . Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012; 31(5):472-8. DOI: 10.1097/ICO.0b013e318225415a. View

Lee J, Ahn H, Kim E, Kim T . Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2010; 30(2):175-9. DOI: 10.1097/ICO.0b013e3181e9adcc. View

Jones L, Downie L, Korb D, Benitez-Del-Castillo J, Dana R, Deng S . TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3):575-628. DOI: 10.1016/j.jtos.2017.05.006. View

Wilson S, Perry H . Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2006; 114(1):76-9. DOI: 10.1016/j.ophtha.2006.05.077. View

Lane S, DuBiner H, Epstein R, Ernest P, Greiner J, Hardten D . A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012; 31(4):396-404. DOI: 10.1097/ICO.0b013e318239aaea. View

10.

Donnenfeld E, Karpecki P, Majmudar P, Nichols K, Raychaudhuri A, Roy M . Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Cornea. 2016; 35(6):741-8. PMC: 4859202. DOI: 10.1097/ICO.0000000000000803. View

11.

Moscovici B, Holzchuh R, Sakassegawa-Naves F, Hoshino-Ruiz D, Albers M, Santo R . Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study. Cont Lens Anterior Eye. 2015; 38(5):373-8. DOI: 10.1016/j.clae.2015.04.004. View

12.

Baudouin C, Sainz de la Maza M, Amrane M, Garrigue J, Ismail D, Figueiredo F . One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. Eur J Ophthalmol. 2017; 27(6):678-685. PMC: 6380090. DOI: 10.5301/ejo.5001002. View

13.

Finis D, Hayajneh J, Konig C, Borrelli M, Schrader S, Geerling G . Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. 2014; 12(2):146-54. DOI: 10.1016/j.jtos.2013.12.001. View

14.

Tong L, Chaurasia S, Mehta J, Beuerman R . Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci. 2010; 51(7):3449-54. DOI: 10.1167/iovs.09-4445. View

15.

Friedman N, Butron K, Robledo N, Loudin J, Baba S, Chayet A . A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. Clin Ophthalmol. 2016; 10:795-804. PMC: 4862385. DOI: 10.2147/OPTH.S101716. View

16.

Semba C, Torkildsen G, Lonsdale J, McLaurin E, Geffin J, Mundorf T . A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012; 153(6):1050-60.e1. DOI: 10.1016/j.ajo.2011.11.003. View

17.

Sheppard J, Torkildsen G, Lonsdale J, DAmbrosio Jr F, McLaurin E, Eiferman R . Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2013; 121(2):475-83. DOI: 10.1016/j.ophtha.2013.09.015. View

18.

Takamura E, Tsubota K, Watanabe H, Ohashi Y . A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012; 96(10):1310-5. PMC: 3463860. DOI: 10.1136/bjophthalmol-2011-301448. View

19.

Lambiase A, Micera A, Pellegrini G, Merlo D, Rama P, De Luca M . In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci. 2009; 50(10):4622-30. DOI: 10.1167/iovs.08-2716. View

20.

Hyden D, Arlinger S . On the sneeze-reflex and its control. Rhinology. 2007; 45(3):218-9. View